Back to Journals » Drug Design, Development and Therapy » Volume 11

Propranolol therapy for infantile hemangioma: our experience

Authors Zhang L, Wu HW, Yuan W, Zheng J

Received 15 February 2017

Accepted for publication 30 March 2017

Published 8 May 2017 Volume 2017:11 Pages 1401—1408

DOI https://doi.org/10.2147/DDDT.S134808

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Qiongyu Guo

Ling Zhang,1,* Hai-Wei Wu,1,* Weien Yuan,2 Jia-Wei Zheng1

1Department of Oral-Maxillary Head and Neck, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai Key Laboratory of Stomatology, Shanghai, 2School of Pharmacy, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Objective: Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a subset of IHs, which develop complications resulting in ulceration, bleeding, or aesthetic deformity. The primary treatment for this subset of IHs is pharmacological intervention, and propranolol has become the new first-line treatment for complicated hemangiomas. Here, we evaluated the efficacy of propranolol on proliferation IH in a clinical cohort including 578 patients.
Methods: We retrospectively reviewed a total of 578 IH patients who were treated with oral propranolol from January 2010 to December 2012. Responses to the propranolol treatment were graded as: excellent, good, poor, or no response. Based on the response to propranolol treatment (once daily at a dose of 1.0 mg/kg for patients younger than 2 months; twice daily at daily total dose of 2 mg/kg for patients older than 2 months), additional pharmacotherapies or surgery were used for IH patients for satisfactory clinical outcome.
Results: Five hundred and sixty (96.9%) of 578 IH patients in our study responded to oral propranolol treatment, and the response rate was significantly different for different ages of patients (P<0.05), with the youngest patients having the highest response rate. The mean time of treatment was 6 months (range, 3–12 months). For example, response rate to propranolol was 98.1% in patients younger than 2 months, compared with 93.3% in patients older than 2 months and younger than 8 months, and 73.7% in patients older than 8 months. One hundred and thirty one patients who exhibited incompletely involuted hemangiomas were further treated with timolol maleate (n=89) or pulsed dye laser (n=42). One hundred and seventeen (89.3%) of 131 patients showed a positive response. There were no instances of life-threatening complications after propranolol. However, minor side effects were observed including 10 (1.73%) cases of sleep disturbance, 7 (1.21%) cases of diarrhea, and 5 (0.86%) cases of bronchospasm.
Conclusion: IH requires early intervention. During the involution phase, tapering propranolol dosage can be done to minimize side effects before discontinuing treatment. For patients exhibiting telangiectasia and chromatosis after propranolol treatment, administration of a 0.5% solution of timolol maleate or pulse dye laser is an effective therapeutic approach for complete involution.

Keywords: propranolol, infantile hemangioma, β-blockers, oral propranolol, intervention studies

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma

Zhang L, Wu H, Yuan W, Zheng J

Cancer Management and Research 2017, 9:279-286

Published Date: 7 July 2017

Biodegradable and biocompatible cationic polymer delivering microRNA-221/222 promotes nerve regeneration after sciatic nerve crush

Song J, Li X, Li Y, Che J, Li X, Zhao X, Chen Y, Zheng X, Yuan W

International Journal of Nanomedicine 2017, 12:4195-4208

Published Date: 2 June 2017

Advances with microRNAs in Parkinson’s disease research

Ma L, Wei L, Wu F, Hu Z, Liu Z, Yuan W

Drug Design, Development and Therapy 2013, 7:1103-1113

Published Date: 1 October 2013

Long-acting preparations of exenatide

Cai Y, Wei L, Ma L, Huang X, Tao A, Liu Z, Yuan W

Drug Design, Development and Therapy 2013, 7:963-970

Published Date: 5 September 2013

pH-sensitive degradable nanoparticles for highly efficient intracellular delivery of exogenous protein

Xu D, Wu F, Chen Y, Wei L, Yuan W

International Journal of Nanomedicine 2013, 8:3405-3414

Published Date: 2 September 2013

Hemostatic absorbable gelatin sponge loaded with 5-fluorouracil for treatment of tumors

Sun W, Chen Y, Yuan W

International Journal of Nanomedicine 2013, 8:1499-1506

Published Date: 18 April 2013

Advances with RNA interference in Alzheimer’s disease research

Chen S, Ge X, Chen Y, Lv N, Liu Z, Yuan W

Drug Design, Development and Therapy 2013, 7:117-125

Published Date: 22 February 2013

Sustained-release G-CSF microspheres using a novel solid-in-oil-in-oil-in-water emulsion method

Liu G, Hong X, Jiang M, Yuan W

International Journal of Nanomedicine 2012, 7:4559-4569

Published Date: 17 August 2012

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats

Yang X, Zheng R, Cai Y, Liao M, Yuan W, Liu Z

International Journal of Nanomedicine 2012, 7:2077-2086

Published Date: 19 April 2012

A scalable fabrication process of polymer microneedles

Yang S, Feng Y, Zhang L, Chen N, Yuan W, Jin T

International Journal of Nanomedicine 2012, 7:1415-1422

Published Date: 12 March 2012